<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02792140</url>
  </required_header>
  <id_info>
    <org_study_id>2015DR2186</org_study_id>
    <nct_id>NCT02792140</nct_id>
  </id_info>
  <brief_title>The Impact of the Opiate Antagonist Naltrexone on the Emotional Valence of Dreams</brief_title>
  <official_title>The Impact of the Opiate Antagonist Naltrexone on the Emotional Valence of Dreams</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bern</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators pose the question which influence the opioid circuit has on
      positive valent situations in dreams.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS-difference concerning the emotional valence of dreams</measure>
    <time_frame>7 days per condition (Naltrexone, Placebo), intermitted by 14 days of washout</time_frame>
    <description>Difference between the mean values of emotional valence of dreams reported in the conditions (Naltrexone, Placebo), as captured in VAS [visual analog scales] for every dream</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Semiquantitative score of emotional valence of dreams</measure>
    <time_frame>7 days per condition (Baseline, Naltrexone, Placebo), intermitted by 14 days of washout</time_frame>
    <description>Based on computational linguistic analysis of the dreams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative score of emotional valence of dreams</measure>
    <time_frame>7 days per condition (Baseline, Naltrexone, Placebo), intermitted by 14 days of washout</time_frame>
    <description>Based on lexical coding of the dreams</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Neuroscience of Dreaming, Healthy</condition>
  <arm_group>
    <arm_group_label>Baseline</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>reporting of dreams</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>daily administration of 50mg Naltrexone, reporting of dreams</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>daily administration of Placebo, reporting of dreams</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>one week</description>
    <arm_group_label>Naltrexone</arm_group_label>
    <other_name>Naltrexin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>one week</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo Pills</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Healthiness

          -  Good capacity of remembering dreams

          -  No opiate consumption

        Exclusion Criteria:

          -  Simultaneous participation in other studies

          -  Addictive disorder

          -  Abnormal liver function

          -  Abnormal kidney function

          -  Hypersensitivity to active ingredient or pharmaceutical additives

          -  Hereditary galactose intolerance

          -  Lactase deficiency

          -  Glucose-galactose malabsorption

          -  Intake of opioid medication
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred Mast, Prof. Dr. phil.</last_name>
    <role>Study Director</role>
    <affiliation>Head of Cognitive Psychology, Perception and Research Methods, Dean Human Sciences Faculty, Ordinarius, University of Bern</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claudio L. Bassetti, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chairman and Head, Department of Neurology Inselspital, Bern University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Bern</name>
      <address>
        <city>Bern</city>
        <zip>3012</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2016</study_first_submitted>
  <study_first_submitted_qc>June 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2016</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psychology</keyword>
  <keyword>Dreams</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Narcotic Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

